Elite in Prurigo Nodularis

Jacek C. Szepietowski

Chalubinskiego Street 1, 
Wroclaw, DS, PL 
Elite in Prurigo Nodularis
Chalubinskiego Street 1, 
Wroclaw, DS, PL 
OverviewLocationsClinical Research

Overview

Jacek Szepietowski practices in Wroclaw, Poland. Mr. Szepietowski is rated as an Elite expert by MediFind in the treatment of Prurigo Nodularis. His top areas of expertise are Hidradenitis Suppurativa, Atopic Dermatitis, Plaque Psoriasis, Kidney Transplant, and Splenectomy.

His clinical research consists of co-authoring 602 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Prurigo Nodularis.

Gender
Male

Locations

Chalubinskiego Street 1, Wroclaw, DS 50368, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 2 Less Clinical Trials

602 Total Publications

Argyria: clinical features which should be remembered.
Argyria: clinical features which should be remembered.
Journal: Polish archives of internal medicine
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Szepietowski's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 27 Advanced Conditions
View All 78 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile